SB17170 Phase 1 Clinical Trial in Solid Tumors

• Status: Not yet recruiting
• Trial end date: 2024-06-30
• Target enrollment: 0
• Participant gender: All

Summary

Phase 1 Open-label, multicenter, dose escalation, dose expansion study

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: SPARK Biopharma

Criteria

Inclusion Criteria:

• A patient with a histologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumors.

• A person who has failed the known standard of care or has developed resistance to the standard of care and no longer has applicable standard of care

• A patient with at least one measurable lesion according to the RECIST v1.1 criteria.

• A person with Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1.

• Those with an expected survival period of 3 months or more at the discretion of of the investigator.

Exclusion Criteria:

• A patient who has received drugs targeting High Mobility Group Box 1 (HMGB1).

• A patient who has received or is undergoing chemotherapy (including chemotherapy, radiation therapy, immunotherapy, hormone therapy, targeted therapy, biological products, and tumor embolization) within 28 days from the first administration date of the investigational drug.

• A person who needs to take contraindicated drugs or is expected to take them during the study period.